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Abstract
Background: Tissue exudates contain low levels of serum complement proteins, and their regulatory effects on prostate
cancer progression are largely unknown. We examined specific serum complement components in coordinating the
activation of tumor suppressors p53 and WWOX (also named FOR or WOX1) and kinases ERK, JNK1 and STAT3 in human
prostate DU145 cells.
Methodology/PrincipalFindings:DU145cellswereculturedovernightin1%normalhumanserum,orinhumanserumdepleted
of an indicated complement protein. Under complement C1q- or C6-free conditions, WOX1 and ERK were mainly present in the
cytoplasm without phosphorylation, whereas phosphorylated JNK1 was greatly accumulated in the nuclei. Exogenous C1q
rapidly restored the WOX1 activation (withTyr33 phosphorylation) in less than2 hr. Without serum complement C9, p53 became
activated, and hyaluronan (HA) reversed the effect. Under C6-free conditions, HA induced activation of STAT3, an enhancer of
metastasis. Notably, exogenous C1q significantly induced apoptosis of WOX1-overexpressing DU145 cells, but not vehicle-
expressing cells. A dominant negative and Y33R mutant of WOX1 blocked the apoptotic effect. C1q did not enhance p53-
mediated apoptosis. By total internal reflection fluorescence (TIRF) microscopy, it was determined that C1q destabilized
adherence of WOX1-expressing DU145 cells by partial detaching and inducing formation of clustered microvilli for focal adhesion
particularly in between cells. These cells then underwent shrinkage, membrane blebbing and death. Remarkably, as determined
by immunostaining, benign prostatic hyperplasia and prostate cancer were shown to have a significantly reduced expression of
tissue C1q, compared to age-matched normal prostate tissues.
Conclusions/Significance: We conclude that complement C1q may induce apoptosis of prostate cancer cells by activating
WOX1 and destabilizing cell adhesion. Downregulation of C1q enhances prostate hyperplasia and cancerous formation due
to failure of WOX1 activation.
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Introduction
Hyaluronic acid or hyaluronan (HA) participates in a remarkably
multitude of cellular and physiologic events, including embryonic
development, morphogenesis, differentiation, inflammation,
wounding healing, immune response, and cancer progression and
metastasis [1–4]. HA is involved in the initiation and progression of
inflammation at both cellular and extracellular levels [5,6]. At the
cellular levels of inflammation, HA recruits neutrophils, activates
macrophages and stimulates dendritic cell maturation. However, in
serum HA may interact with complement proteins. Naturally
occurring polysulfated glycosaminoglycans, such as heparin, restrict
serum complement activation via both classical and alternative
pathways during inflammation [7–10]. The potency of glycosami-
noglycans in inhibiting complement activation depends upon their
extent and positions of polysulfation. Unless conformationally
altered, non-sulfated HA, even at high concentrations (1–5 mg/
ml), cannot restrict complement activation [7,11–13]. Induction of
serum complement activation has been considered as important
strategies in killing cancer cells in vivo [14,15]. Cancer cell-derived
inhibitors for blocking early complement components are known to
enhance cancer growth [16]. Expression of the alternative pathway
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5755inhibitor factor H in lung cancer cells appears to be critical for their
survival [17]. Nonetheless, the functional role of each individual
serum complement component in regulating cancer cell survival is
largely unknown.
Like other tissues, prostate is exposed to exudates from the blood,
which contains low levels of circulating complement proteins.
Whether complement proteins control prostate cell growth and
hyperplasia with age is unknown. Here, by utilizing sera with
selected deletion of complement proteins, we investigated whether
each individual complement protein regulates the activation of
tumor suppressors and kinase proteins in human prostate DU145
cells. These proteins include extracellular-signal regulated kinase/
mitogen-activated protein kinase (ERK or MAPK) [18], WW
domain-containing oxidoreductase (WWOX, FOR, or WOX1)
[19–21], p53 [22], c-Jun N-terminal kinase (JNK1), and signal
transducer and activator of transcription 3 (STAT3) [23–25]. We
determined that without serum complement C1q or C6, the basal
levels of activation or nuclear accumulation of ERK and WOX1
were reduced significantly, whereas constitutive activation of JNK1
occurred. WOX1 is a tumor suppressor and proapoptotic protein
[19–21; reviews].Interestingly,intheabsenceofserum complement
C9, constitutive p53 activation occurred. High molecular size HA
significantly induced the activation ofSTAT3 inDU145,onlywhen
C1q was absent in serum. STAT3 promotes prostate cancer
invasion [23–25]. Finally, C1q alone was able to activate ectopic
WOX1 in killing prostate cancer cells. We discussed the likely
scenario forcirculatingor pericellularHAandcomplement proteins
in regulating cancer cell growth and death via activation of p53,
WOX1, JNK1, and STAT3.
Results
Complement C1q activates tumor suppressor WWOX/
WOX1 in human prostate DU145 cells
We determined whether C1q activates endogenous WOX1 for
nuclear accumulation. Substantial evidence reveals that WOX1 is
a tumor suppressor [19–21,26]. Phosphorylation of WOX1 at
Tyr33 (p-WOX1) is essential for its apoptotic activity both in vitro
and in vivo [27–31]. Nonetheless, during the initial hyperplasia and
cancerous stages, there is a significant upregulation of WOX1
expression and Tyr33 phosphorylation in prostate, skin and breast,
and that the expression is reduced dramatically during malignancy
and metastasis in vivo [21,29,32]. Murine WOX1/Wwox is critical
for postnatal survival, insofar as the knockout mice could survive
for only one month [20,33]. Also, this protein is essential for
normal bone metabolism [33]. The mechanisms regarding the
control for WOX1 to exert prosurvival or proapoptotic functions
remain to be established.
Human DU145 cells were cultured overnight in the presence of
heat-inactivatedfetalbovineserum(10%),followedbystarvationfor
1 hr without serum. These cells were then treated with purified C1q
for 1 hr. Localization of p-WOX1 was determined by immunoflu-
orescence microscopy. These starved cells had very low levels of
cytoplasmic p-WOX1 (Fig. 1A). Exogenous C1q rapidly induced
accumulation of p-WOX1 in the nuclei (Fig. 1B). In comparison,
when the starved cells were cultured in 1% C1q-depleted (DC1q)
human serum for 1 hr, p-WOX1 was mainly localized in the
cytoplasm (Fig. 1C). Reconstitution of DC1q serum with purified
C1qrapidly inducedp-WOX1accumulationin the nuclei(Fig.1D).
Figure 1. Exogenous complement C1q increases p-WOX1 nuclear accumulation in human prostate DU145 cells. (A,B) DU145 cells
were grown on cover glass and cultured overnight in 10% heat-inactivated fetal bovine serum. The cells were then starved under serum-free
conditions for 1 hr, followed by treating with or without purified C1q (1 mg/ml) for 1 hr. Localization of endogenous Tyr33-phosphorylated WOX1 (p-
WOX1) was determined by immunofluorescence microscopy. (C,D) In addition, the starved cells were then cultured in 1% C1q-depleted human
serum (DC1q serum) for 1 hr, in the presence or absence of exogenous C1q (1 mg/ml). (E) Presence of p-WOX1 in the nuclei is shown from counting
,100 cells in 3 experiments (mean6standard deviation).
doi:10.1371/journal.pone.0005755.g001
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apoptosis of DU145 cells
We determined whether C1q activates ectopic WOX1 for
inducing apoptosis. DU145 cells were transfected with EGFP-
WOX1 (tagged with EGFP) or EGFP alone by electroporation.
These cells were cultured overnight (in 10% heat-inactivated fetal
bovine serum), followed by treating with purified C1q for 24 hr. C1q
enhanced WOX1-induced apoptosis and growth suppression of
DU145 cells in a dose-related manner, as revealed by an increased
cell population at the SubG1 phase and a reduced population at the
G0/G1 phase of the cell cycle (Figs. 2A and 2B and Supplementary
Fig. S1). In controls, C1q did not induce apoptosis in DU145 cells
overexpressing EGFP vector only (Figs. 2A and 2B).
The enhancement of apoptosis by C1q was not due to its
activation of complement cascade in the fetal bovine serum,
insofar as the serum was heat-inactivated. Also, under serum-free
conditions, exogenous C1q enhanced ectopic WOX1-mediated
apoptosis (data not shown). These observations suggest that
WOX1 is a downstream effector of C1q-mediated apoptosis,
without involvement of complement activation.
Under similar experimental conditions, we showed that C1q
increased apoptosis in cells overexpressing WOX1. These included
breast MCF7 (Supplementary Fig. S2), and neuroblastoma SH-
SY5Y (Supplementary Fig. S3) and SK-N-SH cells (data not shown).
Again, no effect was observed using cells overexpressing EGFP only.
In parallel, stable transfectants of skin basal cell carcinoma (BCC)
cells for expressing EGFP or human WWOX/WOX1 (hWOX1
tagged with EGFP) were established using G418 selection. By time-
lapse microscopy, we showed that BCC cells expressing EGFP were
resistant to C1q-mediated cell death, whereas hWOX1-expressing
cellsweresensitive to C1q(Fig. 2C). These hWOX1-expressing cells
appeared to exhibit typical morphology of apoptosis, including cell
shrinkage and membrane blebbing.
N-terminal Tyr33-phosphorylated WW domain of WOX1
is responsible for C1q-induced apoptosis of DU145 cells
We determined which domain(s) in WOX1 participates in C1q-
mediated apoptosis of DU145 cells. Human and murine WWOX/
FOR/WOX1 is composed of two N-terminal WW domains, a
nuclear localization sequence, and a C-terminal short-chain
Figure 2. Complement C1q increases ectopic WOX1-induced apoptosis of DU145 cells. (A) DU145 cells were transfected with EGFP-WOX1
(tagged with EGFP) or EGFP alone by electroporation, cultured overnight, and then treated with purified C1q (1 mg/ml) for 24 hr. C1q enhanced
WOX1-induced apoptosis of DU145 cells (see increases in SubG1 phase). In vector controls, C1q did not enhance apoptosis in DU145 cells
overexpressing EGFP. (B) A representative data set from 3 experiments is shown in the bar graph. Similar results were observed by transfecting
DU145 cells with various amounts of WOX1, followed by treating with 1 mg/ml C1q overnight (see Supplementary Fig. S1). WOX1: EGFP-WOX1.
Vector: EGFP only. No ep: cells without electroporation. (C) Stable transfectants of BCC cells for expressing EGFP or EGFP-hWOX1 (human WOX1/
WWOX) were established. By time-lapse microscopy, C1q (1 mg/ml) induced death of hWOX1-expressing cells, but not EGFP-expressing cells. These
hWOX1-expressing cells appeared to undergo typical apoptosis, as they exhibited cell shrinkage and membrane blebbing in a time-related manner. A
representative data is shown from 5 experiments.
doi:10.1371/journal.pone.0005755.g002
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reviews]. A dominant negative-WOX1 (dn-WOX1) was designed
previously, with alterations in the N-terminal first WW domain
[27]. dn-WOX1 is known to block the apoptotic function of p53
and prevent phosphorylation of endogenous WOX1 at Tyr33
[27]. When DU145 cells were transiently overexpressed with dn-
WOX1 (EGFP tag), the cells resisted C1q-induced apoptosis
(Fig. 3). In controls, cells were transfected with an EGFP vector
only, and the cells did not undergo apoptosis in response to C1q
(data not shown or see Fig. 2). In positive controls, non-transfected
cells were treated with staurosporine to induce apoptosis (Fig. 3).
Thus, based on the above observations, the N-terminal WW
domain of WOX1 is likely to be responsible for C1q-induced
activation of WOX1 for killing cancer cells. DU145 cells were
transfected with the N-terminal WW domain of WOX1
(WOX1ww with an EGFP tag) or EGFP only by electroporation
and cultured for 24 hr. By time-lapse microscopy of live cells,
exogenous C1q induced apoptosis of cells expressing the WW
domains (Fig. 4A). Cell shrinkage and nuclear condensation
occurred approximately 100–130 min upon exposure of cells to
C1q. This is a typical event of apoptosis. When DU145 cells were
cotransfected with WOX1ww and dn-WOX1, C1q-induced
apoptosis was lessened (Fig. 4B). Tyr33 phosphorylation in
WOX1 plays a key role in apoptosis both in vitro and in vivo [27–
31]. We altered Tyr33 to Arg33 in the first WW domain [27,35],
and determined that C1q did not mediate apoptosis when cells
expressed this mutant protein (Fig. 4C). In the vector control cells,
no apoptosis was observed (Fig. 4D). C1q-mediated cell death was
not observed in these control cells after a longer incubation for
more than 8–24 hr, which is similar to the aforementioned
observations (Fig. 2).
The C1q/WOX1-induced apoptosis was further confirmed by
internucleosomal DNA fragmentation analysis using agarose gel
electrophoresis. The results showed the cleaved DNA ladders as
induced by C1q in WOX1-expressing DU145 and SH-SY5Y cells
(Fig. 5 and Supplementary Fig. S4). In appropriate control cells
expressing EGFP or nothing, C1q did not induce DNA
fragmentation (Fig. 5 and Supplementary Fig. S4).
C1q does not increase p53-mediated apoptosis
We have shown that tumor suppressor p53 physically interacts
with WOX1, and both proteins may cause apoptosis in a
Figure 3. Dominant-negative WOX1 (dn-WOX1) blocks C1q-mediated apoptosis of DU145 cells. (A) DU145 cells were electroporated
with various amount of dn-WOX1 (EGFP tag) or EGFP alone, followed by culturing for 24 hr. dn-WOX1-expressing cells were treated with C1q (1 mg/
ml) overnight, and cell cycle analysis was performed. EGFP-expressing cells were treated similarly (data not shown). In addition, non-transfected
control cells were treated with or without staurosporine (1 mM) overnight. (B,C) A representative data set for both SubG1 and G0/G1 phases is shown
(from 3 experiments).
doi:10.1371/journal.pone.0005755.g003
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and prevents its degradation [30]. We determined the role of p53
and WOX1 in C1q-regulated cell death. When DU145 cells were
transiently overexpressed with p53, C1q did not significantly
increase the extent of DNA fragmentation (Figs. 5A and 5B). In
combination, both p53 and WOX1 increased the DNA fragmen-
tation. Intriguingly, C1q suppressed the DNA fragmentation in the
p53/WOX1-expressing cells. In agreement with our previous
observations [27], dn-WOX1 was shown to inhibit p53-mediated
DNA fragmentation (Figs. 5A and 5B).
Ectopic WOX1 induces formation of clustered microvilli in
between DU145 cells and C1q enhances the cluster
formation
We examined the cell morphological alterations caused by
ectopic expression with EGFP or EGFP-WOX1 in DU145 cells,
plus the effect of C1q. Time-lapse microscopy showed that C1q
induced shrinkage and membrane blebbing of WOX1-expressing
DU145 and BCC cells during treatment for 2–4 hr or longer
(Figs. 2C and 4A). When DU145 cells were overexpressed with
EGFP and cultured overnight, these resting cells adhered flatly on
the cover glass surface, as determined by total internal reflection
fluorescence (TIRF) microscopy (Fig. 6A). TIRF imaging measures
the protein dynamic events on the cell membrane and cytoskeletal
areas [36,37]. Interestingly, transiently overexpressed EGFP-
WOX1 induced punctate formation on the cell surface, and these
punctates, containing EGFP-WOX1, were mostly clustered in
between cells (Fig. 6B; see arrowheads). At a higher magnification,
these punctates were indeed microvilli, which are needed for focal
adhesion (Fig. 6C). Notably, many of these WOX1-expressing cells
adhered onto the cover glass surface mainly by pericellular
microvilli, as their ventral areas were detached from the surface.
During treatment for 1 hr, C1q significantly increased the
formation of clustered microvilli in between cells (Fig. 6B; see
arrow). This action appears to destabilize cell adhesion for
subsequent shrinking, membrane blebbing and eventual death.
In agreement with our recent report [38], WOX1 can be
associated with cell surface hyaluronidase Hyal-2.
C1q is expressed in the archival prostate tissue samples
and is significantly downregulated in hyperplasia and
cancerous prostate tissues
The above observations suggest that serum- or tissue-derived
complement C1q may induce WOX1 activation in vivo, thereby
restricting cancerous progression. While alterations of human
WWOX gene occur most frequently in prostate and breast
[20,21,34], we examined the expression of C1q in archival
prostate tissues from postmortem patients. By immunofluorescence
microscopy, we determined that compared to age-matched
prostate tissues, C1q is significantly downregulated in benign
prostatic hyperplasia (BPH) and prostate cancer (Figs. 7A and 7B;
1006magnification). At a higher magnification, C1q was shown
to express in the basal and epithelial cells of the archival prostate
tissue samples, and C1q was colocalized with p-WOX1 in these
cells (Fig. 7C).
Serum complement C1q and C6 are essential for
supporting basal phosphorylation of ERK and WOX1 in
DU145 cells
We investigated whether downregulation of C1q in vivo may
reduce the activation of tumor suppressors in vitro, thereby
providing better survival for prostate cancer cells. DU145 cells
were cultured overnight under serum-free conditions, in the
presence of 1% normal human serum, or 1% human serum with
depletion of C1q, C6, C7, C8, or C9. By Western blotting, we
determined that both DC1q and DC6 sera could not support the
constitutive expression of WOX2 (an isoform of WOX1) and p-
ERK in DU145 cells (Figs. 8A and 8B), suggesting that serum C1q
Figure 4. The N-terminal WW domain of WOX1 is associated with C1q-induced apoptosis of DU145 cells. (A) Live DU145 cells-
expressing the N-terminal WW domain (WOX1ww; EGFP tag) were treated with C1q (1 mg/ml), followed by recording morphological changes by
automatic time-lapse microscopy (one frame per 10 min). Cell shrinkage and nuclear condensation occurred approximately 100–130 min upon
exposure of cells to C1q. (B) When cells were cotransfected with WOX1ww and dn-WOX1, C1q-induced apoptosis was significantly reduced. (C)
Alteration of Tyr33 to Arg33 in WOX1 did not cause C1q-mediated cell death. (D) No apoptosis was observed in cells expressing EGFP only upon
exposure to C1q. Compared to the above experiments, C1q concentration was increased for the time-lapse microscopy experiments. A representative
data set is shown from 5 experiments. Approximately 100 cells were examined at the end of time-lapse microscopy. A merged photo of the cell
expressing green fluorescence and the bright field image is shown (prior to challenge with C1q).
doi:10.1371/journal.pone.0005755.g004
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proteins. In comparison, component C7, C8 and C9 did not
support the expression of WOX2 and p-ERK (Figs. 8A and 8B).
Expression of ERK, WOX1, MEK1, and p53 was not significantly
affected by the above-mentioned culture conditions (Figs. 8A and
8B; data not shown for MEK1).
To confirm the aforementioned observations, immunofluores-
cence microscopy was carried out. Cells from the above
experiment were grown on cover glass under identical serum
conditions, then fixed, and stained with specific fluorescence
antibodies. Again, we determined that in the absence of serum
C1q and C6, WOX2 expression was significantly downregulated
in DU145 cells (Fig. 8C). Additionally, when DU145 cells were
cultured in serum without C1q or C6, the levels of p-WOX1 were
significantly decreased in DU145 cells, compared with other
culture conditions, as determined by immunofluorescence micros-
copy (Figs. 8D and 8E). These observations were further
confirmed by Western blotting, which revealed downregulation
of p-WOX1 under C1q-free conditions (Fig. 8F). Under these
conditions, p-WOX1 was present mainly in the cytoplasm of
DU145 cells. No apoptosis was observed in these cells during
24 hr in culture, as determined by the morphology of nuclei
stained with DAPI.
Complement C9 depletion promotes p53 nuclear
accumulation, and hyaluronan stimulates nuclear export
WOX1 physically interacts with p53 both in vitro and in vivo,a n d
may induce apoptosis synergistically [21,26,27,30]. Although
exogenous C1q could not increase p53-mediated apoptosis (Fig. 5),
we examined the effect of serum complement C1q and C6 in
enhancing the basal levels of p53 nuclear accumulation or
activation. When DU145 cells were grown in 1% normal serum
or in serum without C1q or C6, accumulation of p53 in the nuclei
was reduced, as compared to serum-free conditions (Fig. 9A and
9C). Remarkably, without serum C9, p53 was accumulated in the
nuclei (Fig. 9B and 9C), suggesting that serum complement C9 is
able to restrict p53 activation. Under C9-deficient conditions,
exogenous high molecular weight HA induced nuclear export of
p53 to the cytoplasm (Fig. 9B and 9C). In contrast, HA restored p53
nuclear accumulation under C6-free conditions (Fig. 9A and 9C).
Figure 5. C1q-mediated internucleosomal DNA fragmentation in WOX1 and/or p53-expressing DU145 cells. (A) DU145 cells were
electroporated with cDNA expression constructs of WOX1, dn-WOX1 (DN), and/or p53. 24 hr later, the cells were exposed to C1q for 8 hr. In
appropriate controls, cells were electroporated with medium (Sham) or without electroporation (Cont). No DNA fragmentation was shown in these
controls. C1q increased the DNA fragmentation in cells expressing WOX1, but not p53. C1q suppressed p53/WOX1-increased DNA fragmentation. dn-
WOX1 inhibited cell death caused by p53. (B) The intensity of DNA fragmentation was quantified by Photoshop, and averaged results shown in the
bar graph were from two experiments. The ‘‘Sham’’ control (without C1q treatment) is regarded as 0%.
doi:10.1371/journal.pone.0005755.g005
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constitutive JNK1 activation
We have shown that JNK1 physically interacts with WOX1,
and that the binding is increased upon stimulation of cells with UV
light or anisomycin (activator of JNK1) in vitro [27]. Interestingly,
dopaminergic neurotoxin 1-methyl-4-phenyl-pyridinium (MPP
+)
reduces the binding of WOX1 with JNK1 in rat brains [31]. JNK1
blocks the apoptotic function of WOX1 in vitro [27], whereas the
functional antagonism in vivo is unknown. JNK1 and isoforms are
involved in stress and apoptotic responses, cell proliferation, and
many types of diseases [39]. While the above results showed that
complement C1q and C6 supported the activation of WOX1
(Fig. 8), these proteins are predicted to block JNK1 activation, and
depletion of C1q and C6 from sera will cause JNK1 activation.
Under similar experimental conditions, when DU145 cells were
grown in DC1q or DC6 serum, constitutive JNK1 activation
occurred, as determined by both Western blotting (Fig. 10A) and
immunofluorescence microscopy (Fig. 10B).
In the absence of C1q, HA induces STAT3
phosphorylation in DU145 cells
STAT3 activation plays a critical role in prostate cancer cell
invasion [23–25]. HA also participates in cancer invasion, suggesting
that HA activates STAT3 for promoting cancer metastasis. Similarly,
DU145 cells were cultured overnight under various serum-free or -
present conditions. These cells were then exposed to HA for 1 hr. No
activation of STAT3 was observed using normal or complement-
depleted sera (Fig. 10C and 10D). Notably, in the absence of C1q,
HA induced STAT3 activation in DU145 cells (Fig. 10C and 10D),
implying that HA may increase metastasis of C1q-deficient prostate
cancer cells by upregulating STAT3 phosphorylation and suppress-
ing activation of p53 and WOX1. All the above experiments were
performed using medical grade HA from Lifecore. Similar results
were observed using medical grade Healon (data not shown). These
HA preparations are free of protein contamination.
Discussion
The human serum complement cascade is traditionally
considered as a powerful humoral immune system that protects
against invading microorganisms. Nonetheless, the functional
properties of each individual complement component are largely
unknown. In this study, we have demonstrated for the first time
that C1q is expressed in the prostate. Remarkably, C1q expression
is significantly reduced in benign prostatic hyperplasia and
prostate cancer. This event is critical for prostate cancer to grow
and develop. Our supporting evidence is that complement C1q
and C6 sustain the activation of tumor suppressor WOX1, which
is needed for blocking cancer cell proliferation. WOX1 colocalizes
Figure 6. C1q induces cluster formation of WOX1-containing microvilli on the surface in between DU145 cells. (A) When DU145 cells
were transfected with EGFP and cultured overnight, these cells adhered flatly on the cover glass surface, as determined by TIRF microscopy for
measuring the green fluorescence on the cell membrane and cytoskeletal areas (6006magnification). Epi: epifluorescence. (B) In contrast, transiently
overexpressed EGFP-WOX1 induced the formation of punctates, as appeared in clusters, on the cell surface (see arrowheads; 6006magnification).
C1q significantly increased the punctate formation, particularly in between cells (see arrow). Increases in the numbers of punctuates are
approximately 3–6 fold. (C) The clustered punctates, which are rich in EGFP-WOX1 expression, are indeed microvilli on the cell surface (6006
magnification by microscopy and 3x digital magnification).
doi:10.1371/journal.pone.0005755.g006
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Functional significance of this regard remains to be established.
In cell model experiments, we determined that C1q activates
ectopic WOX1 in killing DU145 cells. The sequential event is as
follows: 1) Cells overexpressing WOX1 attach evenly onto the
surface of cover glass (determined by TIRF microscopy), whereas
approximately 50% of cells may ‘‘tiptoe’’ on the glass surface via
formation of microvilli for focal adhesion; 2) C1q dramatically
increases the formation of microvilli as clusters in between cells.
WOX1 can be found in both the focal adhesion areas and in the
nuclei; 3) Cells then undergo shrinkage, membrane blebbing,
nuclear condensation and DNA fragmentation. Exposure of
phosphatidylserine (PS) on the cell surface is barely detectable,
raising the question whether PS exposure is essential for C1q/
WOX1-induced cell death. WWOX/WOX1 has been shown to
localize in the cell membrane/cytoskeleton area [38,40]. We
determined that dominant negative and Y33R mutant of WOX1
blocked the cell death, indicating that Tyr33 activation is essential
for C1q/WOX1-mediated apoptosis. This is in agreement with
our previous observations regarding WOX1-mediated apoptosis
both in vitro and in vivo [26–31,35,38].
In addition to prostate cancer cells, we also showed C1q/
WOX1-induced death of breast and neuroblastoma cells. The
death event could be universal, as long as C1q and WOX1 are
present in both the extracellular and intracellular milieu, and are
sufficient in activating the apoptotic cascade. WOX1 is known to
participate in the early event of apoptosis emanating from the
membrane receptors (e.g. Fas or TNF receptor) [35].
C1q rapidly induces accumulation of activated WOX1 in the
nuclei in non-transfected DU145 cells in less than 2 hr. Without
serum C1q or C6, the nuclear accumulation is blocked. However,
WOX1 nuclear accumulation can be restored by exogenous C1q.
Thus, under physiology conditions, serum C1q and C6 sustain
optimal activation of WOX1 to maintain normal cell physiology.
Figure 7. C1q is expressed in normal archival prostate tissue samples and is significantly downregulated in benign prostatic
hyperplasia (BPH) and prostate cancer. (A) Prostate tissues, including normal prostate, BPH and prostate cancer, were stained with specific
antibody against C1q and then with secondary fluorescent antibody. Nuclei were stained with DAPI (1006magnification). (B) C1q is significantly
downregulated in BPH and prostate cancer, as compared to age-matched prostate tissues (p,0.0001, n=5; Student’s t test). When non-immune
serum was used as the source for primary antibody, no signal was observed (data not shown). (C) C1q is expressed in the basal and epithelial cells of
the archival normal prostate glands (4006magnification). Both C1q and p-WOX1 are colocalized in these cells. Nuclei were stained with DAPI. Similar
results were observed with the archival gland cells from BPH. Compared to the normal prostate tissues, the exposure time for taking the pictures for
BPH was increased. Scale bar, 100 mm.
doi:10.1371/journal.pone.0005755.g007
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membrane hyaluronidase 2 (Hyal-2), followed by recruiting WOX1
and the resulting WOX1/Hyal-2 complex relocation to the nuclei
[38]. Thus, Hyal-2 could be the potential link for C1q/WOX1
signaling. Binding of Hyal-2 with C1q remains to be determined.
C1q did not enhance p53-mediated apoptosis. C1q may
suppress the synergistic effect of p53 and WOX1 in inducing
apoptosis [26,27], suggesting that a balanced p53/WOX1 binding
interaction is needed to control cell survival and death in response
to C1q. Most interestingly, in the absence of C9, serum causes
nuclear accumulation of p53, suggesting that serum C9 controls
p53 activation for regulating gene transcription in vivo. Upon
phosphorylation at key serines such as Ser15, 20 and 46, p53
accumulates in the nuclei [30,41,42]. This implies that cancer cell
growth and invasion can be regulated by serum complement C1q,
C6 and C9 via their regulation of the activation of tumor
suppressor p53 and WOX1. In the absence of serum C1q and C6,
JNK1 becomes constitutively activated, suggesting that C1q and
C6 block JNK1 activation in vivo. These above-mentioned effects
do not appear to be associated with activation of the complement
cascade via both classical and alternative pathways. No activated
complement C3 fragments were shown to deposit on cell surface.
Human tumor suppressor gene WWOX encodes the mRNA for
translating into WWOX/WOX1, WOX2 and other isoforms (if
present) [20,21,43,44]. In the absence of C1q or C6, expression of
WOX2 is downregulated, whereas WOX1 expression is not
affected. These observations indicate that C1q and C6 are likely to
support alternatively splicing of WWOX mRNA, thus leading to
the generation of WOX2 protein. Whether WOX2 acts as a
tumor suppressor is unknown. Presumably, C1q and C6 are
needed for serum-dependent cell survival by maintaining ERK
activation and WOX2 expression. WOX2 may act as a dominant
negative and counteracts the tumor suppressor function of wild
type WWOX/WOX1 in vivo, thereby supporting cancer growth.
Both WOX1 and WOX2 have been shown to be downregulated
in the neurons of Alzheimer’s disease [43]. Indeed, C1q has been
implicated in the pathogenesis of neuronal death in the
neurodegenerative diseases such as in Alzheimer’s disease
[45,46]. There is a strong possibility that C1q activates WOX1
in neurons, which ultimately leads to cell death. Conceivably, the
Figure 8. Complement C1q and C6 are essential for maintaining ERK and WOX1 activation and expression of isoform WOX2. (A,B)
DU145 cells were cultured overnight under serum-free (SF) conditions, or in 1% normal human serum (NHS) or NHS depleted with C1q (DC1q), C6
(DC6), C7 (DC7), C8 (DC8), or C9 (DC9). Significant reduction of isoform WOX2 expression was observed in DU145 cells when cultured in DC1q or DC6
serum (versus SF controls; p,0.001; Student’s t test), whereas DC7, DC8, or DC9 serum was less effective. Activation or phosphorylation of ERK (p-ERK)
was dependent upon the presence of C1q or C6 in serum (versus SF controls; p,0.001; Student’s t test). A representative set of data from 3
experiments is shown. The bar graphs show the average of 3 experiments. (C) The above cells were also grown on cover glass under identical serum
conditions. By immunofluorescence microscopy, serum without C1q or C6 could not support the constitutive expression of WOX2 (p,0.0001, as
versus SF or NHS; Student’s t test). Approximately 200 cells were quantified individually under fluorescence microscopy, and the extent of
fluorescence was subtracted (or normalized) from negative controls (cells stained with secondary antibody only). Nuclei were stained with DAPI. (D,E)
The same cells, as indicated in (A), were stained with p-WOX1 antibody and the extent of protein expression was quantified. (F) Again, identical
experiments were carried out for Western blotting. Under C1q-free conditions (DC1q serum), the basal activation of WOX1 was significantly reduced
(,50% reduction; p,0.001 from versus SF and NHS; Student’s t test; n=3).
doi:10.1371/journal.pone.0005755.g008
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of neuronal WOX1 will determine the extent of C1q/WOX1
signaling and cell death.
Both WOX1 and isoform WOX2 proteins can be upregulated
during the early stages of progression of breast, prostate and other
types of cancers [29,32]. Nonetheless, the C1q/WOX1 signaling
could be less efficient in cancers, as many advanced cancer cells are
deficient in the wild type WWOX/WOX1 [20,21]. Serum C1q and
C6 control the expression of WOX2 and may play a role in
determining tumor progression. Suppressed expression of comple-
ment C6 and C7 mRNAs has been shown in patients with
oesophageal carcinoma and colon and kidney cancers [47].
Functional significance of this finding relative to tumorigenesis and
activation of p53, WOX1, ERK and JNK1 remains further
investigation.
Complement C6 deficiency has been shown to prolong tail
bleeding, along with reduced platelet aggregation, in transgenic
animals [48]. Also, absence of C6 protects against sepsis mortality
in rats [49]. Nonetheless, the role of serum C6 in the development
of solid tumors and leukemia has never been established. In
contrast, single nucleotide polymorphism in the C1qA component
of complement correlates with the pattern of clinical breast cancer
metastasis [50]. C1q interacts with specific membrane receptors to
regulate immune responses [51,52]. In addition, C1q interacts
with a cellular membrane type-1 matrix metalloproteinase that
may regulate cancer progression and metastasis [53]. Presence of
membrane C6 receptor is not known and remains to be
investigated.
Both HA and hyaluronidases are significantly elevated in the
circulation in patients with prostate cancer [54,55] and especially
in metastatic cancers [3,4]. While a relatively constant amount of
HA is in circulation [3,4], these HA polymers indeed regulate the
physiological function of normal blood leukocytes, leukemia and
cancerous cells via membrane CD44 and other receptors. Our
data showed that HA tends to increase p53 relocation to the
cytoplasm, suggesting that p53 can readily undergo a rapid
turnover by the ubiquitination/proteasomal system in the
cytoplasm. Conceivably, this mechanism to reduce wild type p53
would help facilitate prostate cancer cell growth. Interestingly, HA
stimulated p53 nuclear export, when DU145 cells were cultured
under serum-free or C9-free conditions. In contrast, HA induces
p53 nuclear import, when cells were grown in serum without C6.
Thus, serum C6 and C9 may compete for controlling the
activation of p53.
Activation of STAT3 signaling pathway is critical for prostate
cancer invasion [23–25]. Of particular interest is that HA induced
phosphorylation of STAT3 in DU145 cells when cultured in the
absence of C1q. These observations further imply that downreg-
ulation of C1q enhances prostate hyperplasia and cancerous
formation due to failure of WOX1 activation and increased
activation of STAT3.
We have shown that conformationally altered HA restricts
hemolytic function of the complement classical pathway and
blocks the expression of WOX1 in DU145 cells [7,12,13]. Serum
complement proteins are likely to be restricted by HA via binding
to the accessible polyanionic charges within a disrupted HA matrix
rather than an intact HA matrix. Heat-induced alteration of HA
conformation is likely to occur under inflammatory conditions in
vivo. Hyaluronidase digestion definitely causes changes in HA
conformation, especially in patients with metastatic cancer.
In summary, we have presented a novel functional role of
complement C1q and C6 in regulating the expression of WOX2
and activation of ERK, JNK1 and WOX1. Also, complement C9
controls nuclear localization or activation of p53. HA participates
in cancer progression and metastasis, and also modulates the
effects of C1q and C6, along with STAT3 activation. Our findings
have apparently added a new feature of complement proteins in
regulating cancer cell survival and progression. We believe that the
serum environment, which contains complement proteins and
circulating hyaluronan, affects the behavior of cancer cells and
Figure 9. p53 accumulates in the nuclei of DU145 cells cultured in complement C9-free serum, and HA reverses the nuclear
accumulation. DU145 cells were cultured overnight in each indicated serum with depletion of a specific complement protein. p53 localization in
the cells was determined by immunofluorescence microscopy. (A) In the absence of complement C6 (DC6 serum), p53 was mainly present in the
cytoplasm. High molecular size HA (50 mg/ml) induced nuclear accumulation of p53 during treatment for 1 hr. (B) In the absence of serum C9 (DC9
serum), p53 was mostly localized in the nuclei, and HA (50 mg/ml) induced nuclear export in 1 hr. (C) To determine nuclear localization of p53,
approximately 200 cells were counted. Shown in the bar graph is an average of results form two experiments. (D) In negative controls, cells were
stained with Texas Red-conjugated secondary antibody only. SF, serum free; NHS, normal human serum.
doi:10.1371/journal.pone.0005755.g009
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analysis for complement protein expression in cancer cells is
needed to elucidate the crucial role of complement components in
regulating cancer cell progression and metastasis.
Materials and Methods
DU145 cells, specific complement component-depleted
human sera, antibodies, and cDNA expression constructs
Human prostate cancer cell line DU145 was cultured overnight
under serum-free conditions, or in the presence of 0.5 or 1%
normal human serum (NHS), or DC1q (C1q depleted; from
Sigma-Aldrich and Quidel), DC6 (C6 depleted; Quidel), DC7 (C7
depleted; Quidel), DC8 (C8 depleted; Quidel), or DC9 serum (C9
depleted; Quidel). We examined the expression and phosphory-
lation of ERK, WOX1, and other indicated proteins by Western
blotting [26,27]. Under stress conditions, WOX1 undergoes
phosphorylation at Tyr33 both in vitro and in vivo [26,27].
Specific antibodies against WOX1, WOX2, and its Tyr33-
phosphorylated form (p-WOX1) were produced in rabbits, as
described [26–31]. Additional specific antibodies used in this study
were against the following proteins: 1) p53, JNK1, p-JNK1
(phosphorylation at Thr183 and Tyr185), p-ERK (Tyr204
phosphorylation) from Santa Cruz Biotechnologies, 2) p-STAT3
(Tyr705 phosphorylation) and STAT3 from New England
BioLab, 3) ERK from BD Transduction Laboratory, and 4) C1q
from Quidel. Where indicated, the cultured cells were treated for
1 hr with medical grade Healon (highly purified high-molecular-
size HA; 50 mg/ml). In addition, medical grade HA used for
testing was from Lifecore, a kind gift of Dr. G. Armand of the
Glycomed Research, Hastings-on-Hudson, New York.
Immunofluorescence microscopy and single cell imaging
analysis
DU145 cells were cultured on cover slides under serum free
conditions, or in the presence of 1% NHS, or NHS depleted with
an indicated complement component, for 16–24 hr. These cells
were treated with or without HA for 1 hr (50 mg/ml), followed by
processing immunofluorescence microscopy using dual antibodies
[26,27]. We examined the expression and localization of ERK,
WOX1, p53, STAT3 and other indicated proteins by immuno-
fluorescence microscopy. Appropriate secondary antibodies,
conjugated with Texas red or Alexa Flour, were from Rockland
and Molecular Probes/Invitrogen, respectively. Nuclei were
Figure 10. Serum C1q and C6 restrict constitutive JNK1 activation but have no effect on STAT3. (A) DU145 cells were cultured under
serum-free (SF) conditions, or in 1% NHS, DC1q or DC6 serum for 16–24 hr. In the absence of C1q and C6, spontaneous JNK1 activation occurred
(versus SF controls; p,0.001; Student’s t test), as determined by Western blotting. A representative set of data is shown from 3 experiments. (B)
Similar results were observed by immunofluorescence microscopy, which shows significant JNK1 activation or nuclear accumulation under serum
C1q- and C6-free conditions (versus SF; p,0.001; Student’s t test, n=3). DC9 serum had no effect. Approximately 200 cells were counted from each
experiment. (C,D) There was no STAT3 activation in DU145 cells under all the indicated serum conditions. Under C1q-free conditions, HA (50 mg/ml)
effectively induced STAT3 phosphorylation in cells during treatment for 1 hr. Approximately 200 cells were counted from each experiment (n=3).
doi:10.1371/journal.pone.0005755.g010
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imaging analysis was performed by Photoshop CS2 (Adobe) and
Image-Pro Plus (Media Cybernetics). Where indicated, expression
of two selected proteins in ,200 cells in randomly specified areas
was quantified. In negative controls, cells were stained with
secondary antibody only. The resulting background fluorescence
was used to subtract the positive signals from using a specific
primary antibody staining for the cell imaging (using the Image-
Pro Plus software). Data were calculated and presented as
mean6standard deviation. Student’s t test was used for statistical
analyses.
Human postmortem prostate tissues
We obtained medical and legal consent to acquire postmortem
prostate tissues from the autopsy service at the Department of
Pathology, University of Colorado Health Sciences Center (by CI
Sze). The tissues included patients with benign prostatic hypertro-
phy (BPH), prostatic adenocarcinoma, and age-matched normal
prostatetissues(5each).De-parafinizationand immunofluorescence
staining were performed similarly as described above [29,43].
Primary antibodies used in the immunofluorescence were against:
C1q (Quidel) and p-WOX1 [27]. Secondary antibodies were anti-
rabbit IgG FITC and anti-mouse IgG Texas Red. In negative
controls, secondary antibodies were used for staining only.
Cell cycle analysis, BCC stable transfectants, and time-
lapse microscopy of live cells
DU145 cells were transfected with a WOX1-p-EGFPC1 or an
‘‘empty’’ p-EGFPC1 construct by electroporation (20 mg of DNA/
3610
6 cells; 200 Volt and 50 millisecond; BTX ECM 830 Square
Wave Electroporator, Genetronics) [26,27], followed by culturing
for 16–24 hr. These cells, with transient expression of fluorescent
proteins, were then treated with purified C1q (1–5 mg/ml; from
Quidel and Sigma-Aldrich with similar purity and potency) or
medium alone for 8–24 hr. Propidium iodide staining and cell
cycle analysis were carried out using a fluorescence-activated cell
sorting (FACS)/flow cytometery machine (BD) to measure the
extent of apoptosis or growth inhibition [27]. The extent of green
fluorescence was normally greater than 60%. Cell death caused by
electric shock from electroporation was gated out, and the rest of
the cell populations were subjected to analyses. A dominant
negative WOX1 construct was developed [27], and used to block
C1q-mediated cell death. Where indicated, DU145 cells-express-
ing EGFP-WOX1, EGFP-WOX1ww (WW domains only), or
EGFP were treated with C1q (1 mg/ml) and subjected to time-
lapse microscopy at 37uC and 5% CO2/atmosphere conditions
for determining cell morphological changes, including cell
shrinkage, membrane blebbing, and nuclei condensation, using a
Nikon Eclipse TE-2000S inverted microscope. In addition, we
established stable transfectants of skin basal cell carcinoma (BCC)
[56] for expressing EGFP or EGFP-hWOX1 (human WOX1/
WWOX). These cells were established from G418 selection
[26,27]. Time-lapse microscopy was performed using these cells to
determine C1q-mediated cell death.
Total internal reflection fluorescence (TIRF) microscopy
TIRF microscopy utilizes evanescent wave to selectively
measure the cell surface and cytoskeletal areas of approximately
100 nm in depth. Surface plasmon-enhanced two-photon fluores-
cence microscopy for live cell membrane imaging was developed,
as described [37,57]. A Nikon Eclipse microscope was modified for
measuring fluorescent signals on the cell surface [37,57]. DU145
cells were cultured on pieces of cover glass overnight, followed by
exposure to C1q (1 mg/ml) for 1 hr. The live cells were imaged, or
they were fixed with 4% paraformaldehyde for imaging.
Supporting Information
Figure S1 Complement C1q increases WOX1-induced apopto-
sis of DU145 cells (a dose-related experiment). (A) DU145 cells
were transfected with various amounts of EGFP-WOX1 (tagged
with EGFP; 2.5–10 mg) by electroporation. The cells were then
cultured overnight and treated with purified C1q (1 mg/ml) for
24 hr. (B,C) C1q enhanced WOX1-induced apoptosis of DU145
cells (see the increases in SubG1 phase but decreases in the G0/G1
phase). A representative data set (bar graphs) is shown from 3
experiments. In control experiments, C1q did not enhance
apoptosis in DU145-overexpressing EGFP (data not shown). In
positive controls, non-transfected DU145 cells were treated with
staurosporine (1 mM) for 8 hr, prior to cell cycle analysis. WOX1:
EGFP-WOX1.
Found at: doi:10.1371/journal.pone.0005755.s001 (0.40 MB TIF)
Figure S2 Complement C1q enhances ectopic WOX1-induced
apoptosis of breast MCF7 cells. (A) MCF7 cells were transfected
with EGFP-WOX1 or EGFP alone by electroporation. Following
overnight culture, these cells were treated with purified C1q
(1 mg/ml) for 24 hr. C1q enhanced apoptosis of MCF7 cells
transiently overexpressing EGFP-WOX1. In controls, C1q did not
enhance apoptosis in MCF7-overexpressing EGFP (data not
shown). In positive controls, non-transfected MCF7 cells were
treated with staurosporine (1 mm) for 8 hr, followed by cell cycle
analysis. In another control, the cells received medium only. The
number on the top of each bar is the percentage of cell numbers
(bar graphs at right). (B,C) Shown in the bar graphs is a
representative data set from 3 experiments. WOX1: EGFP-
WOX1. Control: cells without electroporation. Stauro: cells
treated with staurosporine.
Found at: doi:10.1371/journal.pone.0005755.s002 (0.40 MB TIF)
Figure S3 Complement C1q enhances ectopic WOX1-induced
apoptosis of neuroblastoma SH-SY5Y cells. (A) SH-SY5Y cells
were transfected with EGFP-WOX1 or EGFP alone by electro-
poration. Following overnight culture, these cells were treated with
purified C1q (1 mg/ml) for 24 hr. C1q enhanced apoptosis of SH-
SY5Y cells overexpressing EGFP-WOX1. In controls, C1q did not
enhance apoptosis in SH-SY5Y-overexpressing EGFP (data not
shown). (B,C) A representative data set is shown as bar graphs
from 3 experiments. WOX1: EGFP-WOX1.
Found at: doi:10.1371/journal.pone.0005755.s003 (0.68 MB TIF)
Figure S4 Complement C1q enhances ectopic WOX1-induced
internucleosomal DNA fragmentation of DU145 and SH-SY5Y
cells. (A) DU145 cells were electroporated with the indicated
vectors and then cultured for 24 hr, followed by exposure to
purified human C1q (1 mg/ml) for 8 hr. C1q increased DNA
fragmentation in WOX1-expressing DU145 cells. In negative
controls, cells were electroporated with nothing, or witout
electroporation (no ep). Staurosporine (1 mM)-treated cells were
regarded as positive controls. (B) Similar results were obtained by
testing SH-SY5Y cells.
Found at: doi:10.1371/journal.pone.0005755.s004 (1.52 MB TIF)
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